1. US FDA. Tymlos™ (abaloparatide) injection, for subcutaneous use: US prescribing information. 2017.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208743lbl.pdf
. Accessed 30 May 2017.
2. Culler MD, Dong J, Shen Y, et al. BIM-44058, a novel analog of PTHrP with enhanced bone building activity, but decreased calcium-mobilization potential [abstract no. M460]. J Bone Miner Res. 2001;16(Suppl 1):M460.
3. Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722–33.
4. Hattersley G, Dean T, Corbin BA, et al. Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology. 2016;157(1):141–9.
5. US FDA. Novel drug approvals for 2017. 2017.
https://www.fda.gov/drugs/developmentapprovalprocess/druginnovation/ucm537040.htm
. Accessed 30 May 2017.